Treatments in the European League Against Rheumatism Scleroderma Trials and Research cohort
| Total | MD (%) | lcSSc | dcSSc | p Value(lcSSc vs dcSSc) | Other | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients, n (%) | 1820 (100) | 1095 (60.2) | 669 (36.8) | 56 (3.1) | ||||||
| Dosage | % | Median | % | Median | % | Median | % | Median | ||
| Prednisone (mg/day) | 45.3 | 8 | 7.7† | 37.0 | 7.5 | 59.3 | 10 | *** | 39.0 | 5 |
| Cyclophosphamide (mg per last 4 weeks) | 15.9 | 1000 | 5.1† | 9.6 | 1000 | 26.6 | 1000 | *** | 8.3 | 1000 |
| Methotrexate (mg per week) | 13.7 | 12 | 8.6† | 12.8 | 10 | 15.1 | 15 | NS | 15.9 | 15 |
| Bosentan (mg/day) | 9.5 | 250 | 10.8† | 7.1 | 250 | 12.6 | 250 | *** | 22.0 | 125 |
| Azathioprine (mg/day) | 6.4 | 100 | 9.7† | 6.4 | 100 | 6.2 | 100 | NS | 12.2 | 50 |
| Sildenafil (mg/day) | 4.5 | 60 | 10.9† | 3.7 | 60 | 5.8 | 60 | NS | 4.9 | 57.5 |
| Mycophenolate mofetil (500 mg tablets/day) | 4.2 | 4 | 8.7† | 2.6 | 4 | 6.6 | 4 | *** | 6.8 | 3 |
| d-Penicillamine (mg/day) | 2.1 | 300 | 9.8† | 2.0 | 300 | 2.5 | 300 | NS | 0 | NA |
| Rituximab (cumulative dosage since last visit in mg) | 1 | 2000 | 10.8† | 0.3 | 2000 | 2.2 | 2000 | *** | 0 | NA |
| drug | total | lcSSc | dcSSc | Other | ||||||
| Proton pump inhibitor, % | 65.2 | 2.5 | 65.1 | 65.2 | NS | 66.7 | ||||
| Calcium channel blocker, % | 52.7 | 3.0 | 55.3 | 50.4 | * | 26.5 | ||||
| ACE inhibitor | 20.8 | 3.5 | 19.7 | 23.5 | NS | 11.5 | ||||
| Iloprost intravenously, % | 15.6 | 3.7 | 14.4 | 15.5 | NS | 40.8 | ||||
| NSAIDs, % | 14.7 | 3.1 | 15.6 | 13.4 | NS | 11.8 | ||||
| Diuretics, % | 13.0 | 3.6 | 14.1 | 11.2 | NS | 12.5 | ||||
| Angiotensin-receptor blocker, % | 8.2 | 4.0 | 8.4 | 6.3 | NS | 28.0 | ||||
| β Blocker, % | 6.6 | 3.8 | 6.6 | 6.6 | NS | 8.0 | ||||
| Oxygen, % | 2.8 | 4.1 | 2.3 | 3.6 | NS | 2.1 | ||||
| Other pulmonary vasodilator, % | 2.7 | 5.2 | 3.2 | 2.0 | NS | 0 | ||||
| α Blocker, % | 1.7 | 4.7 | 1.5 | 2.2 | NS | 0 | ||||
| Digitalis, % | 1.2 | 3.8 | 1.2 | 1.2 | NS | 0 | ||||
| Sitaxentan, % | 0.7 | 4.1 | 0.8 | 0.8 | NS | 0 | ||||
| Inhalation of iloprost, % | 0.6 | 4.2 | 1.0 | 0.2 | NS | 0 | ||||
| Imatinib, % | 0.5 | 5 | 0.2 | 0.9 | NS | 0 | ||||
Median refers to patients receiving medication.
↵* p<0.05; ***p<0.001; treatment documentation belongs to the newly introduced items (available since online documentation has started, find additional patient characteristics in online supplementary table S2).
↵† Interpretation of registered data is controversial (blank fields might be interpreted as treatment not given at all or as missing data entry, further discrimination is not feasible).
ACE, angiotensin converting enzyme; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; MD, missing data; NA, not applicable; NS, not significant; NSAIDs, non-steroidal anti-inflammatory drugs.